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ABSTRACT
We examined the chemotactic response of eosinophils 
to five eosinophil chemotactic factors (ECF; ECF-P15, 
-P16, -P17, -P18 and -P19) from an established T cell line 
(ST02) in 31 patients with bronchial asthma (BA). The 
asthmatic patients were divided into three groups 
according to the ratio of the chemotactic response to 
ECF-P15 and -P19 (P15/P19). A type 1 response occurred 
when eosinophils responded to both ECF-P15 and to
ECF-P19, a type 2 response occurred when eosinophils 
responded to ECF-P15 only and a type 3 response 
occurred when eosinophils responded to ECF-P19 only. 
Of 31 asthmatic patients, 21 exhibited a type 2 
response, six exhibited a type 1 response and the 
remainder exhibited a type 3 response. In contrast, 23 
of 25 healthy donors exhibited a type 1 response and
none of them exhibited a type 2 response. This typing 
of asthmatic patients was apparently correlated with 
the clinical symptoms of the patients. All patients 
exhibiting a type 1 response were diagnosed with mild 
and episodic asthma and none of them had taken oral 
prednisolone. In contrast, many patients exhibiting a 
type 2 response were diagnosed with moderate, 
persistent and perennial asthma. Indeed, eight of 
these 21 patients had taken oral prednisolone. The
patients exhibiting a type 3 response were diagnosed 
with mild to moderate and episodic asthma, but none 
of them had taken oral prednisolone. Furthermore, 
according to the total percentage migration to five 
ST02-derived ECF, asthmatic patients were further 
divided into two groups: high- and low-responding 
groups. Sixteen of 21 patients exhibiting a type 2
response belonged to the high-responding group, 
whereas all patients exhibiting a type 1 or type 3 
response belonged to low-responding group. The 
present results indicate that such chemotactic 
heterogeneity of eosinophils to STO2-derived ECF is 
closely associated with the severity of BA, particularly 
with regard to the necessity of steroid therapy.
Key words: bronchial asthma, chemotaxis, disease 
severity, eosinophil chemotactic factor, eosinophil, 
heterogeneity.
INTRODUCTION
It is well known that bronchial asthma (BA) is not a single 
dise se entity, but is a syndrome of which the cause is 
complex. According to its pathogenesis, BA is classified 
into atopic and non-atopic asthma. A classification of BA 
bas d on severity is of importance when decisions have 
to be made regarding management, because asthma
therapy has a stepwise approach, in which the level of 
therapy is increased as the severity of the asthma
increases.1 A significant correlation between the severity 
of BA and laboratory data, such as blood eosinophil 
count,2,3 forced expiratory volume in the first second 
(FEY1)4 and the serum level of eosinophil cationic protein
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(ECP),5,6 has been described. However, the laboratory 
data described seem not to be sufficient for the 
evaluation of disease severity. Therefore, it appears to be 
important to find laboratory data that are useful in the 
evaluation of the disease severity of BA.
 Eosinophils are heterogeneous in their density: 
normodense and hypodense.7,8 In patients with allergic 
rhinitis (AR), an increased percentage of hypodense 
eosinophils has been found more often in patients with 
moderate to severe AR than in subjects with none to mild 
disease.9 In patients with allergic asthma, a significant
correlation has been shown between the percentage of 
peripheral hypodense eosinophils and disease severity, 
as represented by FEV1.10 Separately, we have shown that 
eosinophils from eosinophilic patients are heterogeneous 
in the chemotactic response to five different eosinophil 
chemotactic factors (ECE; ECF-P15, -P16, -P17, -P18 and
-P19) derived from an established T cell line (STO2).11-15 
For example, eosinophils from Kimura's disease (KD) and 
hypereosinophilic syndrome are attracted by ECF-P15 and 
-P16, but not by other STO2-derived ECE,11 whereas 
eosinophils from patients with KD exhibiting eruption 
respond to all five ECF13
 We have also shown that chemotactic responses of 
eosinophils to ECF-P15 and -P16 are significantly higher at 
exacerbation than those at remission in patients with 
atopic dermatitis, indicating that chemotactic response 
may be a useful tool in the evaluation of disease severity.16 
It becomes of interest to clarify whether such a hetero-
geneous response is also observed in patients with BA. 
 The purpose of the present study was to show that the 
chemotactic response of eosinophils in asthmatic patients 
is closely associated with the disease severity of BA.
METHODS
Patients
We examined 31 patients with BA (16 male, 15 female). 
Written informed consent was obtained from all subjects. 
The diagnosis of BA was made by clinical symptoms 
(cough, chest tightness, wheezing and dyspnea), reversal 
airflow limitation (FEY1, forced vital capacity and peak 
expiratory flow rate (PEFR)), daily variability of peak 
expiratory flow and measurements of allergic status. In 
several patients, bronchial hyperresponsiveness 
expressed by the provocative concentration causing a 
20% fall in FEY1 (PC20)-acetylcholinewas also examined. 
According to the International Consensus Report on
T eatment of Asthma (gauging the severity of the disease 
as defined by the Japanese Society of Allergology17), 14 
patients were mild, 16 patients were moderate and one 
patient was severe. Patients were required to have been
receiving a stable dose of medications for 3 months and 
were required to continue the same dose of all 
medicat ons over the course of the study as there have 
be  many discussions of the effects of drugs on the 
chemotactic response.18-22 Eight of 31 patients were
taking oral prednisolone and nine of them were taking 
non-steroidal anti-allergic drugs. The backgrounds of the 
subjects are shown in Table 1 and the laboratory findings 
are shown in Table 2. None of the subjects had any 
history of respiratory infection or acute exacerbation 
within 1 month prior to the study.
Chemoattractants
Recombinant human interleukin (IL)-3, IL-5, granulocyte 
macrophage-colony stimulating factor (GM-CSF) and 
RANTES were used as chemoattractants. Interleukin-3, 
GM-CSF, RANTES and macrophage inflammatory
protein-1α (MIP-1α) were purchased from Genzyme
(Boston, MA, USA). Interleukin-5 was a kind gift from the 
Suntory Institute for Biomedical Research (Osaka, Japan). 
 Cultured supernatants of STO2 were fractionated on 
an isoelectric electrophoresis system to prepare five ECF 
(ECF-P15, -P16, -P17, -P18 and -P19).12 In a previous study
w  found that ECF-P15 was a mixture of IL-3, IL-5, GM-
CSF and another unidentified ECF (ECF-P15).11 Therefore, 
ECF-P15 was used in the presence of neutralizing 
antibodies against IL-3, IL-5 and GM-CSF in the present
experiments. The remainder of the STO2-derived [CF 
differed from identified eosinophil chemoattractants, 
such as RANTES, eotaxin and MIP-1a, in their 
antigenicity, heparin affinity and function.11,23
Chemotaxis
Recombinant human IL-3 (10-1000U/mL), IL-5 
(10-1000U/mL), GM-CSF (10-1000U/mL), RANTES
(1-100ng/mL), MIP-1α(1-100ng/mL), complement
C5a (10-7 to 10-9mol/L; Sigma Chemical Co., St Louis, 
M0, USA) and five STO2-derived ECF were used in the 
pre ent experiments. The same preparations of the ECF 
w r  used throughout the present experiments.
 Heparinized peripheral blood was obtained from 
healthy donors and from 31 asthmatic patients who had 
no or little clinical symptoms at that time. Leukocytes were
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Table 1. Backgrounds of asthmatic patients
enriched by dextran sedimentation. Subsequently, 
normodense eosinophils were separated on a discon-
tinuous density Percoll column (Pharmacia, Uppsala, 
Sweden), as previously described,16 followed by isolation 
with immunomagnetic beads using CD16. The purity
of the eosinophil was more than 97% and viability was 
more than 95%. In some experiments, eosinophils were 
further fractionated into normodense (density >1.082) 
and hypodense (density <1.082) eosinophils according to 
the method previously described.11
 Chemotaxis was assessed by a modification of the 
meth d previously described using a 48-well chemotaxis 
chamber with a 5pm pore polyvinylpyrolidone-free 
nuclep re filter in triplicate assays.11 After incubation of
eosinophils (0.5-1×106/mL) at 37℃ for 2h, the cells
that passed through the filter to the lower surface were 
fixed, stained with Duff-Quick (Midori Juji, Osaka, Japan)
○nd counted on nine high-power fields (h. P. f.; 40×10)
using a calibrated graticule. Chemotactic response was 
expressed as percentage migration. The most potent
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Table 2. Laboratory findings of asthmatic patients
percentage migration among percentage migrations 
towards each chemoattractant at various concentrations 
was presented as percentage migration to the chemo-
attractant. Percentage migration was calculated 
according to the following formula:
% Migration=(no. migrated eosinophils/no. input
eosinophils)×100
Statistical analysis
Statistical analysis was performed using the software 
program StatView J-4.5TM (Abacus Concepts Inc., 
Berkeley, CA, USA) on a Power MacintoshTM personal 
computer (Apple Computer Inc., Cupertino, CA, USA).
Results are expressed as the meanSEM. Differences 
between groups were analyzed using Chi-squared 
statistics and an analysis of variance (ANOVA).
RESULTS
Chemotactic response of eosinophils
We assessed the chemotactic response of normodense 
eosinophils from 25 healthy donors and from 31 asthmatic 
patients to ECF as described above. As shown in Fig. l , we 
divided the subjects into 3 groups according to the chemo-
tactic response of eosinophils to STO2-derived ECF (type
1, type 2 and type 3 responses), particularly to the ratio of 
percentage migration to ECF-P15 and -P19 (P15/P19). 
Eosinophils classified as exhibiting a type 1 response 
responded similarly to both ECF-P15 and -P19 (0.5 <
P15/P19 <2.0). In contrast, eosinophils exhibiting a type 2 
response preferentially responded to ECF-P15 (P15/P19 > 
2.0) and eosinophils exhibiting a type 3 response 
responded preferentially to ECF-P19 (P15/P19 <0.5).
 The typing of the chemotactic response of the six 
asthmatic patients was repeated during their clinical 
course. Thus, we found that the typing of five of six
patients did not change, suggesting that the typing of 
asthmatic patients was not easily changeable. 
Furthermore, the typing of one patient changed from a 
type 1 to a type 2 response when the severity of his 
asthma changed from mild to moderate.
 As shown in Fig. 2, eosinophils from 23 of 25 healthy 
donors exhibited a type 1 response. The remainder of the 
healthy donors exhibited a type 3 response and none of 
them exhibited a type 2 response. In contrast, 21 of 31
asthmatic patients exhibited a type 2 response. Six and 
four of these patients exhibited a type 1 and type 3 
response, respectively. The results indicate that the 
chemotactic response of eosinophils in asthmatic
patients differs from that of healthy donors (X2=31.3; 
P<0.001).
 We also found that the asthmatic patients could be 
further divided into two groups: high-(>20%) and low-
responding (<20%) groups (Fig. 3). All patients 
exhibi ng a type 1 and type 3 response belonged to low-
responding group, whereas 16 of 21 patients exhibiting a 
typ  2 response belonged to the high-responding group 
(x2= 15.7; P<0.001). The results suggest that
osinophils of patients with severe asthma are in a much 
more activated form with regard to their chemotactic 
response to STO2-derived ECF than are eosinophils from 
patients with mild asthma.
 We further found that there is no essential difference in 
the chemotactic response to STO2-derived ECF between 
normodense and hypodense eosinophils (data not 
shown).
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Fig. 1 Typing of the chemotactic response of eosinophils to STO2-derived eosinophil chemotactic factors (ECF). Chemotactic 
response of (a) eosinophils from normal donors, (b) eosinophils from patients showing a type 1 response, (c) eosinophils from
patients showing a type 2 response and (d) eosinophils of patients showing a type 3 response. One representative datum from each
type is shown. Dota represent the meon±SEM chemotactis response to STO2-derived ECF obtained in triplicate ond show a
representative response from each group. PBS, phosphate-buffered saline.
Fig. 2 Eosinophil chemotactic response in healthy donors
(n=25) and in asthmatic patients (n=31). The percentage of
each type of chemotactic response is shown:(■), Type 1;(□),
ｔype 2;(□),type 3.
Correlation between the chemotactic response 
and clinical characteristics
The clinical characteristics of each type of response are 
summarized in Table 3. The patients exhibiting a type 1 
response were characterized as patients with mild, 
episodic asthma and none had taken oral prednisolone. 
In contrast, patients exhibiting a type 2 response were
characterized as patients with moderate, persistent and 
perennial asthma. Indeed, eight of 21 patients who 
exhibited a type 2 response required oral prednisolone 
treatment for management of their clinical symptoms.
The patients who exhibited a type 3 response were 
characterized as patients with mild to moderate, episodic 
asthma and none of them had taken oral prednisolone. 
There was no difference in the other medications taken by
232 T OHNISHI ET AL.
Fig. 3 Total per cent migration of eosinophils in asthmotis potients to STO2-derived eosinophil chemotactic factors was calculated
as described in Methods. (■), type 1 response;(□)type 2 response;(□), type 3 response.
Table 3. Clinical characteristics of asthmatic patients
the patients, such as the oral b-adrenoceptor agonist 
theophyl ine and antiallergic drugs, among the three 
groups. These results indicate that the chemotactic
response of eosinophils in asthmatic patients is closely 
associated with the clinical symptoms of the asthma, 
particularly with regard to disease severity.
 Concerning the difference between patients who 
exhibited a type 1 and type 3 response, the duration from 
the onset of asthmatic symptoms in patients exhibiting a
type 3 response was clearly shorter than for patients 
exhibiting a type 1 response, although the difference was 
not significant (Table 3).
We also assessed the chemotactic response of
eosinophils to GM-CSF, IL-3, IL-5, RANTES, MIP-1α and
C5a, which have been widely accepted as chemo-
attractants for eosinophils. As shown in Fig. 4, the
chemotactic response to GM-CSF, IL-3 and IL-5 was 
higher in patients exhibiting a type 2 response than in 
patients who exhibited a type 1 or a type 3 response; 
however, there was no significant difference between
patients exhibiting type 2 versus type 1 or type 3 responses. 
In contrast, the response to C5a was significantly higher in 
patients who exhibited a type 2 response than in patients 
who exhibited either a type 1 or type 3 response
(P<0.005). Interestingy, RANTES ond MIP-1α only
weakly attracted eosino-phils, even those exhibiting a 
type 2 response, and there was no significant difference in 
the chemotactic response of the eosinophils among the 
three groups (Fig. 4).
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Fig. 4 Chemotactic response of
eosinophils to identified eosinophil
chemotactic factors. (■), type l
chemotactic response of eosinophils;
(■), type 2 chemotactic response;
(□), type 3 chemotactic response.
Data represent the mean±SEM
chemotactic response of eosinophils
from each group.*P<0.005. PBS,
phosphatee-buffered saline; GM-CSF,
granulocyte macrophage-colony
stimulating factor; IL, interleukin;
MIP-1α, macrophage inflammatory
protein-1α; C5a, complement C5a.
Correlation of the chemotactic response with 
laboratory characteristics
The laboratory characteristics of each type of response 
are summarized in Table 4. We found that peripheral 
blood eosinophil number, plasma levels of ECP and 
IgE-KIST for type 2 response were higher than for type 1 
or type 3 responses, but no significant difference was 
observed. In contrast, the PEFR for type 2 and type 3 
responses were significantly lower than for type 1 
responses (P<0.001).
DISCUSSION
In the present paper we have demonstrated that the 
chemotactic response of eosinophils from asthmatic 
patients varies according to their clinical and laboratory 
findings. Asthmatic patients can be divided into three 
groups according to the ratio of the chemotactic 
response eosinophils to ECF-P15 and -P19. Eosinophils
exhibiting a type 1 response are attracted by both ECF-
P15 and -P19 to a similar degree (0.5<P15/P19<2.0), 
those exhibiting a type 2 response are preferentially 
attracted by ECF-P15 (P15/P19>2.0) and those exhibiting 
a type 3 response were preferentially attracted by ECF-
P19 (P15/P19<0.5). Although most eosinophils from 
healthy donors exhibited a chemotactic response similar 
to the type 1 response, many asthmatic patients exhibited
a type 2 response (P<0.001). Patients exhibiting a type 
2 response are characterized as moderate asthmatic 
patients who require steroid therapy, whereas the patients
Table 4. Laboratory data of asthmatic patients in three groups
exhibiting a type 1 and type 3 response are classified 
as having mild asthma and who never require 
therapy (P<0.001). The results indicate that the typing 
of the chemotactic response is closely associated with the 
clinical characteristics of the asthma, particularly with the 
requirement of steroid therapy and the disease severity.
 Although steroid treatment is eventually useful in the 
therapy of allergic disorders including BA, long-term oral 
or parenteral steroid treatment sometimes induces severe 
side effects, such as osteoporosis, arterial hypertension, 
diabetes, hypothalamic-pituitary-adrenal axis suppres-
sion, cataracts, obesity, skin thinning, leading to 
cutaneous striae and easy bruising, and muscle weak-
ness.' Therefore, it becomes important to differentiate 
patients who do not require steroid therapy from asthmatic 
patients who do, if possible. As shown in Table 3, there is 
no patient who requires steroid therapy among the
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patients exhibiting a type 1 or type 3 response, although 
eight of 21 patients exhibiting a type 2 response require 
oral prednisolone treatment. It is thus suggested that it is 
possible to differentiate patients who do not require 
steroid treatment from asthmatic patients who do on the 
basis of typing of the chemotactic response using the 
chemotactic heterogeneity of eosinophils.
 There has been increasing evidence2-6 that some 
laboratory data are significantly associated with the 
disease severity. For instance, the blood eosinophil count 
and serum ECP levels have been shown to be significantly 
correlated with bronchial hyperresponsiveness, 
represented by methacholine sensitivity, and severity by 
FEV1.2-6 Although it is likely that these data are useful to
evaluate disease severity, we infer that they may have a 
disadvantage in that a single measurement may not allow 
us to precisely evaluate the severity of BA. Only 
combining measurements of laboratory variables and 
lung function during the course of BA will yield a 
characterization of the disorder according to its severity.
 Several reports have been published concerning 
the up-regulation of the chemotactic response of 
eosinophils from asthmatic patients to IL-5,24 IL-8,25,26 
platelet-activating factor27 and formyl-methionyl-leucyl-
phenylalanine.25 However, chemotactic response to the 
chemoattractants has been compared between asthmatic 
patients and normal donors in all the studies cited above.
Little discussion has occurred regarding the difference in 
the chemotactic response of eosinophils among 
asthmatic patients. In the present paper we have also 
confirmed up-regulation of the chemotactic response of 
eosinophils to defined chemoattractants, such as IL-3, IL-
5, GM-CSF and C5a (but not RANTES and MIP-1 ), in 
asthmatic patients. Only the chemotactic response to
C5a is significantly different among the three groups. By 
using such defined chemoattractants it seems to be 
difficult to classify asthmatic patients by a single 
assessment of a chemotactic assay. However, the present 
results suggest that it is possible to evaluate the disease 
severity of asthmatic patients, even by a single 
assessment of the chemotactic response to our STO2-
derived ECF
 Asthmatic patients can be further divided into two 
groups: high- and low-responding groups. Eosinophils of 
all patients exhibiting type 1 and type 3 response belong 
to the low-responding group, whereas those exhibiting
a type 2 response belong to the high-responding 
group (x2=15.7; P<0.001). This may imply that 
eosinophils of patients with severe asthma are in much
more activated form than are those from patients with 
mild asthma.10 It is well known that eosinophils are 
heterogeneous in their density. It has been proposed that
hypodense eosinophils are in an activated form, whereas 
normodense eosinophils are in the resting state.2a,29 
However, it has been shown that the chemotactic response 
of hypodense eosinophils is similar to that of normodense
e sinophils.11,30 It is thus suggested that the density of 
eosinophils is not associated with the heterogeneous 
response of eosinophils to STO2-derived ECF. 
 Although the relationship between the chemotactic 
response of eosinophils and the clinical and laboratory 
findings is still unclear at present, we propose herein that
asthmatic patients can be divided into three groups 
according to their chemotactic response to ECF-P15 and 
-P19, hich is closely associated with the severity of BA, 
particularly with regard to the requirement for steroid 
therapy.
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